Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults.^[6] It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.^[6][8][9] It is administered by intravenous infusion every 3 months.^[6]

Eptinezumab was approved for medical use in the United States in February 2020.^[10][11]

The U.S. Food and Drug Administration (FDA) approved eptinezumab based primarily on evidence from two clinical trials (Trial 1/ NCT02559895 and Trial 2/ NCT02974153) of 1741 subjects with chronic or episodic migraine headaches.^[11] Trials were conducted at 212 sites in United States, Georgia, Russia, Ukraine and European Union.^[11]

The benefit and side effects of eptinezumab were evaluated in two clinical trials of adult subjects 18 – 71 years of age with a history of migraine headaches.^[11] The trials had similar designs.^[11]

Trial 1 enrolled subjects with a history of episodic migraine headaches and Trial 2 enrolled subjects with chronic migraine headaches.^[11] Subjects were assigned to receive one of two doses of eptinezumab or placebo injections every three months for a total of twelve months in Trial 1, and for a total of 6 months in Trial 2.^[11] Neither the subjects nor the health care providers knew which treatment was being given until the trial was completed.^[11]

The benefit of eptinezumab in comparison to placebo was assessed based on the change in the number of migraine days per month during the first three-month treatment period.^[11]

• Galcanezumab
• Erenumab